drugset / Trial / NCT00768469
Study Evaluating Safety And Tolerability, Solid Tumor
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.
Timeline
- Start
- 2008-10
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | 160 mg | Oral |
| Subject | Neratinib | Small molecule | 240 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |